← Browse by Condition
Medical Condition

vaginal atrophy patients with gsm

Total Trials
1
Recruiting Now
1
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for vaginal atrophy patients with gsm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — vaginal atrophy patients with gsm Clinical Trials

How many clinical trials are currently recruiting for vaginal atrophy patients with gsm?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for vaginal atrophy patients with gsm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for vaginal atrophy patients with gsm?
vaginal atrophy patients with gsm research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a vaginal atrophy patients with gsm clinical trial?
Eligibility criteria for vaginal atrophy patients with gsm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Centre Hospitalier Universitaire Saint Pierre 1 trial

Recruiting Clinical Trials

NCT06828640
Recruiting
Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
Enrollment
160 pts
Location
Belgium
Sponsor
Centre Hospitalier Universitai...
View Trial →

Related Conditions

vulvo vaginal atrophy (1) genitourinary syndrome of menopause gsm (1) vaginal atrophy in breast cancer patients (1) treatment (1) sexual disfunction (1) dyspareunia female (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology